Aptevo Therapeutics (APVO) shares were surging early Thursday after the company said all of the patients with acute myeloid leukemia treated with its mipletamig bispecific antibody achieved remission within 30 days of treatment in a phase 1b trial, including two patients in the cohort who experienced complete remission with 100% elimination of cancer cells.
The results build on data from the company's prior trial of the immune-oncology therapeutics platform, where 100% of the frontline patients also achieved remission, it said.
The phase 1b/2 dose optimization trial is investigating mipletamig as frontline therapy in up to 39 patients across five dosing levels in combination with venetoclax and azacitidine, which are the current standard of care for acute myeloid leukemia.
Price: 11.99, Change: +1.98, Percent Change: +19.78
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。